Sanofi Says Au Revoir To Viehbacher, But Is It Committing A Faux Pas?
Executive Summary
The French pharma's abrupt dismissal of its CEO, citing execution problems with its best-selling drug and issues with management style, has investors wondering whether Chris Viehbacher should have gotten the benefit of the doubt from the company’s board, given his impressive track record.
You may also be interested in...
Sanofi’s Revamped Business Structure Includes Three New Pharma Units
The French pharma said it will operate with five global business units beginning in January 2016: General Medicines & Emerging Markets, Specialty Care, Diabetes & Cardiovascular, Sanofi Pasteur and Merial.
Sanofi’s Revamped Business Structure Includes Three New Pharma Units
The French pharma said it will operate with five global business units beginning in January 2016: General Medicines & Emerging Markets, Specialty Care, Diabetes & Cardiovascular, Sanofi Pasteur and Merial.
Sanofi’s Revamped Business Structure Includes Three New Pharma Units
The French pharma said it will operate with five global business units beginning in January 2016: General Medicines & Emerging Markets, Specialty Care, Diabetes & Cardiovascular, Sanofi Pasteur and Merial.